Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2015-08-11 06:32:39
Reporting Period:
Filing Date:
Accepted Time:
2015-08-11 06:32:39
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1360886 Osiris Therapeutics Inc. OSIR Biological Products, (No Disgnostic Substances) (2836) 710881115
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1636236 Alla Danilkovitch C/o Osiris Therapeutics, Inc.
7015 Albert Einstein Drive
Columbia MD 21046-1707
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-08-10 5,000 $0.40 10,375 No 4 M Direct
Common Stock Disposition 2015-08-10 2,425 $18.22 7,950 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2015-08-10 5,000 $0.40 5,000 $0.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
93,000 2006-12-01 2015-12-01 No 4 M Direct
  1. Represents the same-day sale exercise of non-qualified stock options granted under our Amended and Restated 1994 Stock Incentive Plan, whereby 5,000 options were exercised and 2,425 shares were concurrently retired to pay the exercise cost and taxes on the related gain, resulting in the net issuance of 2,575 shares of common stock.